We measured the ability of kanamycin-treated KMAP or live MAP to kill moDCs upon infection, by measuring cell viability via flow cytometry on the CD11c+CD11b+ population, which was ~96% homogenous in our experiments [27] (Figure S1). The gene discussed is ITGAX; the disease is infection.